`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`EYENOVIA, INC.,
`Petitioner,
`
`v.
`
`SYDNEXIS, INC.,
`Patent Owner.
`
`
`Case No. IPR2022-00384
`U.S. Patent No. 10,842,787
`
`
`
`DECLARATION OF THOMAS H. WINTNER
`
`
`
`
`
`
`
`Eyenovia Exhibit 1059
`Eyenovia, Inc. v. Sydnexis, Inc.
`IPR2022-00384
`Page 1 of 6
`
`
`
`Case No. IPR2022-00384
`Patent No. 10,842,787
`
`
`I, Thomas H. Wintner, do hereby declare:
`
`1.
`
`I am a member in the law firm of Mintz, Levin, Cohn, Ferris, Glovsky
`
`and Popeo P.C. (“Mintz Levin”). Lead counsel in this inter partes review
`
`proceeding is Peter J. Cuomo, who is also a member at Mintz Levin. Mr. Cuomo
`
`is registered to practice before the United States Patent and Trademark Office and
`
`holds Registration No. 58,481. With respect to this proceeding, I will work closely
`
`with Mr. Cuomo.
`
`2.
`
`I am a member in good standing of the Bar of the Commonwealth of
`
`Massachusetts. My Massachusetts Bar membership is 667329. I am admitted to
`
`practice before the Supreme Court of the United States, the United States Courts of
`
`Appeals for the Federal, First, Fourth, Sixth, and Ninth Circuits, and the United
`
`States District Court for the District of Massachusetts.
`
`3.
`
`I have appeared pro hac vice in multiple IPR proceedings, one PGR
`
`proceeding, and one derivation proceeding before the U.S. Patent and Trademark
`
`Office:
`
` Amphastar Pharmaceuticals, Inc. v. Aegis Therapeutics, LLC,
`IPR2021-01324;
`
` Samsung Electronics Co., Ltd., et al. v. Nanoco Technologies Ltd.,
`IPR2021-00182, -00183, -00184, -00185, -00186;
`
` Laboratory Corporation of America Holdings v. Quest Diagnostics
`Investments LLC, IPR2019-00738, -01425, -01517, -01618;
`
` Jennewein Biotechnologie GmbH v. Glycosyn LLC, PGR2019-00023;
`
`2
`
`Eyenovia Exhibit 1059, Page 2 of 6
`
`
`
`Case No. IPR2022-00384
`Patent No. 10,842,787
`
`
`
` Indivior Inc. v. Rhodes Pharmaceuticals L.P., IPR2018-00795;
`
` Green Cross Corp. v. Shire Human Genetic Therapies, Inc., IPR2016-
`00258;
` Sawai USA Inc. and Sawai Pharmaceutical Co., Ltd v. Nissan
`Chemical Industries, Ltd., IPR2015-01647, -01648;
` Mylan Pharmaceuticals Inc. v. Nissan Chemical Industries, Ltd.,
`IPR2015-01069; and
` Ethertronics, Inc. v. Nextivity, Inc., DER2016-00021.
`
`4.
`
`In my sixteen years of litigation practice I currently represent or have
`
`represented clients in numerous chemical and biotechnology patent litigation cases
`
`in various United States federal courts and the International Trade Commission.
`
`Those actions include:
`
` Nanoco Technologies Ltd. v. Samsung Electronics Co., et al. (E.D.
`Tex. Case No. 2:20-cv-00038-JRG)
` In the Matter of Certain Human Milk Oligosaccharides and Methods
`of Producing the Same, Investigation No. 337-TA-1120 (International
`Trade Commission, May 2019)
` Rhodes Pharmaceuticals L.P. v. Indivior Inc. (D. Del. No. 16-01308)
` Kowa Company, Ltd., et al. v. Amneal Pharmaceuticals LLC (Fed.
`Cir. Case No. 2018-1051)
` Green Cross Corp. v. Shire Human Genetic Therapies, Inc. (Fed. Cir.
`Case No. 2017-2071)
` Kowa Company, Ltd., et al. v. Aurobindo Pharma Limited, et al.
`(S.D.N.Y. No. 14-2497)
` Kowa Company, Ltd., et al. v. Amneal Pharmaceuticals LLC
`(S.D.N.Y. No. 14-2758)
`
`3
`
`Eyenovia Exhibit 1059, Page 3 of 6
`
`
`
`Case No. IPR2022-00384
`Patent No. 10,842,787
`
`
` Kowa Company, Ltd., et al. v. Mylan Inc., et al. (S.D.N.Y. No. 14-
`2647)
` Kowa Company, Ltd., et al. v. Orient Pharma Co., Ltd. (S.D.N.Y. No.
`14-2759)
` Kowa Company, Ltd., et al. v. Sawai USA, Inc., et al. (S.D.N.Y. No.
`14-5575)
` Kowa Company, Ltd., et al. v. Zydus Pharmaceuticals (USA) Inc., et
`al. (S.D.N.Y. No. 14-2760)
` Kowa Company, Ltd., et al. v. Apotex, Inc., et al. (S.D.N.Y. No. 14-
`7934)
` Takeda Pharmaceutical Co. v. Mylan, Inc., No. 12-00024 (S.D.N.Y.)
` Mitsubishi Chemical Corp. v. Barr Laboratories, Inc., 718 F. Supp.
`2d 382 (S.D.N.Y. 2010), affirmed, No. 2010-1432, 2011 WL 3288394
`(Fed. Cir. Aug. 2, 2011).
` Roquette Frères v. SPI Pharma, Inc., No. 06-540 (D. Del. Oct. 4,
`2010)
`
`5.
`
`In addition to my J.D. obtained from the University of Virginia
`
`School of Law, I hold a B.A. in chemistry, summa cum laude, from Williams
`
`College, and an M.A. in bioorganic chemistry from Harvard University, where I
`
`was a National Science Foundation Fellow. Accordingly, I am comfortable and
`
`experienced with technically and legally complex matters such as those raised in
`
`this inter partes review proceeding. In particular, I am experienced with
`
`technically and legally complex matters in the fields of organic chemistry,
`
`bioorganic chemistry, biochemistry, and molecular biology.
`
`4
`
`Eyenovia Exhibit 1059, Page 4 of 6
`
`
`
`Case No. IPR2022-00384
`Patent No. 10,842,787
`
`
`6.
`
`I am familiar with U.S. Patent No. 10,842,787 (“the ’787 patent”), its
`
`prosecution history, and the legal subject matter, technical subject matter, and prior
`
`art discussed in Petitioner’s request for inter partes review of the ’787 patent.
`
`7.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body, nor has a court or administrative body denied my
`
`application for admission to practice. I have not been sanctioned or cited for
`
`contempt by any court or administrative body.
`
`8.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in Part 42 of 37 C.F.R.
`
`9.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq., and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`10.
`
`I declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like are punishable by fine, imprisonment, or both, under
`
`Section 1001 of Title 18 of the United States Code.
`
`
`
`
`
`
`
`5
`
`Eyenovia Exhibit 1059, Page 5 of 6
`
`
`
`Case No. IPR2022-00384
`Patent No. 10,842,787
`
`
`Respectfully submitted,
`
`
`
`
`
`
`/Thomas H. Wintner/
`Thomas H. Wintner
`MINTZ, LEVIN, COHN, FERRIS,
`GLOVSKY AND POPEO P.C.
`One Financial Center
`Boston, MA 02111
`(617) 542-6000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: August 2, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`Eyenovia Exhibit 1059, Page 6 of 6
`
`
